10 Feb 2025

Alephoson’s CEO and Founder, Dr. Benjamin Lee, was interviewed by the SOUTH CHINA MORNING POST (SCMP), a leading Hong Kong newspaper, on Eye-Drug Delivery Technology and Clinical Trials.

Read the full article here

Title: Hong Kong biotech start-up Alephoson eyes international trial for eye-drug delivery

Eric Ng
Published: 9:30am, 10 Feb 2025
A Hong Kong biotech start-up is working with a number of university partners to conduct global clinical trials that could lead to a better way of delivering drugs for prevalent eyediseases. Alephoson Biopharmaceuticals, established in 2019, has developed a technology to combine a proprietary cell-penetration peptide (CPP) compound with biologic medication that is currently used to treat age-related macular degeneration (AMD) and diabetes-related macular edema (DME). If planned clinical trials are successful, this could result in the commercialization of a medication that can be administered via eyedrops instead of an injection into the cavity at the back of the eye, according to Benjamin Lee, a founder and CEO of Alephoson, which is based in the Hong Kong Science and Technology Park. “As a research-and-development-focused company, we are forging partnerships with university hospitals in Hong Kong, mainland China, Asia and the United States on our planned clinical trials,” Lee said. “Upon completion of a preclinical toxicity study in around 12 months, our target is to request authorization from the US Food and Drug Administration to conduct Phase 1 and 2a investigational drug trials by the first quarter of next year.” The idea of using CPP as a drug delivery system originated from Professor Wei Gang, an Alephoson co-founder, who is deputy director of the Department of Pharmaceutics at Shanghai’s Fudan University. “As a visiting scholar at the University of Maryland in the US in 2008, I learned to design peptides as a conduit for drug delivery and thought of applying that in ophthalmology,” Wei said. “Subsequent experiments showed particularly good results on safety and efficacy penetrating into the back of the eye.” Dr. Marten Brelen, an Alephoson scientific adviser, is the principal investigator on the planned Phase 1 trial with AMD patients on safety, side effects, best dosage, and treatment timing. It will be funded by a grant under the Hong Kong government’s General Research Fund for supporting university investigations. Currently, the main component of first-line drugs for AMD and DME is anti-vascular endothelial growth factors (anti-VEGFs), which are far superior compared to second-line laser and steroid treatments, because of better a safety profile, lower side effect risks and better visual acuity outcomes,” he said.

“The challenge of anti-VEGFs is that the molecules are too large to be given as eyedrops, hence patients are burdened with having to endure regular needle injections into the back of the eye, typically for four to five years.” Brelen is an associate professor of ophthalmology and visual sciences at the Chinese University of Hong Kong (CUHK). He is also an eye surgeon at the Prince of Wales Hospital and the Hong Kong Eye Hospital. The eye injections carry a risk of potentially serious side effects, including infection, cataract and retinal detachment, according to the UK’s Milton Keynes University Hospital NHS Foundation Trust. In Hong Kong, they cost around HK$10,000 (US$1,284) for each shot and are not paid for by the public health system, Brelen said. If patients miss or delay treatment for slowing or stopping abnormal growth of blood
vessels that leak damaging fluids into the light-sensitive tissues of the eye, they risk visual deterioration. Alephoson plans to conduct its first clinical trial involving 40 to 60 DME patients at university hospitals in Hong Kong, Singapore, Taiwan, South Korea and the US, Lee said. It will be led by Professor Nguyen Quan at the Byers Eye Institute at Stanford University. Alephoson is close to completing its Series A fundraising that seeks to raise US$10 million, which would fund preclinical and Phase 1/2a clinical work, he said. AMD is the most common cause of vision loss among people age 50 and older, according to researchers at Johns Hopkins University. Globally, about 1.85 million people were estimated to be blind due to AMD in 2020, while another 6.23 million were moderately to severely vision-impaired because of it, according to findings from the Global Burden of Disease Study’s vision loss expert group, published last July. The prevalence of DME among diabetics was estimated to be 5.47 per cent globally, based on seven studies that evaluated 58,592 patients, according to a 2022 University of Toronto study. The number of people living with diabetes quadrupled to 830 million in 2022 from 1990, the World Health Organization estimated in November.

Eric Ng
FOLLOW
Eric joined the Post in 1998 after brief stints in a trading company, and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has over 20 years of experience covering China’s energy, mining and industrial materials sectors, and has reported on China’s healthcare and biotechnology sectors for three years. Currently, he leads the Post’s coverage on climate change, energy transition and sustainability topics. Eric has a Masters of Business

奧朗生物醫藥有限公司在7月26日舉辦的“眼部疾病治療的新視野”會議上展示了其技術創新和投資潛力。參會人員包括50多人，其中包括啟明創投、複健資本、海爾資本等投資機構，以及複星醫藥、華潤醫藥等生物醫藥企業。

會議由奧朗生物醫藥有限公司主辦，展銀投資和江蘇銀行提供支持，於7月26日在環球港江蘇銀行個人私行會議室舉行。會議主題是“眼部疾病治療的新視野”，旨在探討當前眼部疾病治療面臨的挑戰和未來的發展方向。

奧朗生物醫藥的顧問斯坦福大學教授Quan Dong Nguyen和香港中文大學教授Mårten E BRELÉN在會上發表演講，對當前的AMD和DME治療進行了探討。他們指出，目前治療存在很大的未滿足臨床需求，無創新型製劑亟需開發。同時，他們也分享了一些新的治療思路和方法。

復旦大學魏剛教授也在會上彙報了創新眼科製劑的研發進展，並介紹了利用穿膜肽進行眼科藥物遞送的優勢。穿膜肽是一種可以促進藥物通過細胞膜進入細胞內部的分子，可以提高藥物的生物利用度和治療效果。魏剛教授表示，穿膜肽遞送技術是目前眼科藥物遞送領域的一個重要發展方向，未來將有很大的應用前景。他的報告引起了與會者的廣泛關注和討論。

奧朗生物醫藥公司的代表介紹了其關鍵產品CPB202的技術特點和臨床應用前景。作為一款同類首創的突破性療法，CPB202可以實現無針製劑有效治療眼後新生血管疾病，解決了上百萬病患玻璃體注射引發各種副作用的問題。該產品具有重要的臨床價值，並有望成為未來眼科治療領域的重要突破。此外，奧朗生物醫藥公司還介紹了其未來的發展計畫。公司期望融資10M美元，以推動IND申報過程，並進行臨床試驗。這將有助於加速CPB202的上市進程，並為公司未來的發展提供更多支持。

總之，此次“眼部疾病治療的新視野”會議為行業內專家、學者和企業提供了一個交流和合作的平臺，為中國眼科治療領域的發展注入了新動力。相信在各方共同努力下，未來將會有更多創新型產品和技術問世，為廣大患者帶來更好的治療效果和健康保障。

On July 26th, 2023, Alephoson Biopharmaceuticals Limited hosted a conference and showcased it’s technological innovation and investment potential, with the support from DIBC and the Bank of Jiangsu’s, where it was held at it’s private banking ballroom of the Global Harbor Center, Shanghai. With the theme “A New Horizon in Eye Disease Treatment” , the conference was attended by over 50 participants, including representatives from venture capital firms, such as Qiming Venture Partners, Fuson Capital, Haier Capital, Yonghua capital and ZUIG investment as well as pharmaceutical companies such as Fosun Pharma, China Resources Pharmaceutical, ZHAOKE Ophthalmology and Boan Biotech. The sessions aimed to explore the challenges and the latest developments of eye disease treatments.

Professor Quan Dong Nguyen from Stanford University and Professor Mårten E BRELÉN from The Chinese University of Hong Kong, who are both scientific advisors to Alephoson Biopharmaceuticals, also presented at the conference, discussing the current treatment of Age- Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). They pointed out that there are significant unmet medical needs in current treatments, and innovative formulations urgently need to be developed. They also shared some new treatment ideas and methods.

Professor Gang Wei from Fudan University also presented his research progress to develop innovative ophthalmic formulations and introduced the advantages of using cell-penetrating peptides for ophthalmic drug delivery. Cell-penetrating peptides are molecules that can promote drug entry into cells through the cell membrane and improve drug bioavailability and therapeutic effects. Professor Wei stated that cell-penetrating peptide delivery technology is an important development direction in the field of ophthalmic drug delivery and has great application prospects in the future. His report received extensive attention and discussions among the participants.

Dr. Benjamin LEE, founder & CEO of Alephoson Biopharmaceuticals introduced the technical characteristics and clinical application prospects of their key product, CPB202. Aiming to become a first-in-class drug, CPB202 can effectively treat neovascular age-related macular degeneration for millions of patients without the need for needle injections, thus avoiding the various side effects associated with intravitreal injections. This product has significant clinical value and is expected to become an important breakthrough in the field of ophthalmic treatment.

Alephoson Biopharmaceuticals also introduced its future development plan. The company expects to raise USD $10 million to promote the Investigational New Drug (IND) application process and conduct phase I clinical trials for CPB202. The fund will accelerate the listing process of CPB202 and provide solid support for the company’s future development.

In summary, the “A New Horizon in Eye Disease management” conference provided a platform for industry experts, scholars, and companies to communicate and cooperate, injecting new momentum into the development of China’s ophthalmic treatment field. We believe that with the joint efforts of all parties, more innovative products and technologies will emerge in the future, bringing better treatments and health care to patients.